Filter Results:
(991)
Show Results For
- All HBS Web
(991)
- People (4)
- News (256)
- Research (615)
- Events (9)
- Multimedia (24)
- Faculty Publications (396)
Show Results For
- All HBS Web
(991)
- People (4)
- News (256)
- Research (615)
- Events (9)
- Multimedia (24)
- Faculty Publications (396)
- 01 Sep 2008
- News
In Africa, Porter Sees Lessons for Health Care
delivery systems of both developing and advanced countries: fragmentation, inefficiency, and organization around discrete interventions (such as delivering drugs or screening) rather than integrated care. Porter and his colleagues aim to... View Details
- 08 Mar 2016
- First Look
March 8, 2016
cultural model and undermine their own positions with inappropriate use of symbolic market-creation actions. Download working paper: https://www.hbs.edu/faculty/Pages/item.aspx?num=50701 Harvard Business School Case 916-026 Express Scripts: Promoting Prescription View Details
Keywords: Sean Silverthorne
- 01 Mar 2017
- News
Alumni Take Cold Calls in New York City
focused on 23andMe, whose sale of genetic testing kits directly to consumers was challenged by the Food & Drug Administration. Quelch, who coauthored the case, is also on the faculty of the Harvard T.H. Chan School of Public Health. The... View Details
- 18 Aug 2017
- Op-Ed
Op-Ed: Courageous Leader Triggers a Moral Revolt of CEOs Against Trump
actions was not without risk for the CEOs and their companies” While many CEOs prefer to stay under the radar and avoid public scrutiny, Ken Frazier led the way with his example. As the chair of PhRMA, the pharmaceutical manufacturers association, Frazier has led the... View Details
Keywords: by Bill George
- 07 Oct 2014
- News
Network Effect
was shocked by their advice. “They said, ‘Try three Advil a day. It might help. There are a few FDA-approved drugs for Alzheimer’s disease, and they won’t help,’” he recalls. McCance, a venture- capital pioneer with Greylock Partners, had... View Details
Keywords: Linda Kush
- 01 Dec 2013
- News
To Market, to Market
chirality) of drug molecules with a high degree of accuracy for drug development and diagnostic applications. Chemical compounds excreted by predators that stimulate avoidance behavior in disease-carrying... View Details
- Portrait Project
Sarah Assayag
I would become the first colony settler on Earth 2.0, develop drugs that would allow humans to become immortal, and create an android that would fall asleep by counting electric sheep. My 8-year-old self, inspired by science fiction,... View Details
- 02 Feb 2021
- Blog Post
Finding My Focus in Health care Amidst a Global Pandemic
can redefine the Health care industry and sparked my interest in exploring how the public and private sectors can work together to improve patient outcomes. With the summer internship search heating up, I am excited to explore opportunities as an intern at the Food and... View Details
- 24 Jun 2016
- News
Reinventing Pharma
2004) began her career as a research scientist. Eventually expanding her responsibilities into business development led her to HBS, where she hoped to solidify her understanding of the intersection of science and business. Following graduation, she joined Novartis,... View Details
- 01 Jun 2002
- News
Late Start, Dramatic Finish
the availability and cost of drugs used to treat HIV and AIDS in Africa. Fueled by doughnuts and an unsinkable team spirit, the HBS group worked for 24 hours straight to formulate the winning action plan. “We decided not only to design a... View Details
- 12 Jul 2020
- Research & Ideas
Solving COVID'S Mental Health Crisis
for everyone and also highlighted the important link between research, discovery, and cure." The GPP is a statewide prevention program aimed at reducing the use of dangerous drugs among teens and young adults through awareness campaigns,... View Details
- 20 Dec 2018
- Research & Ideas
Most Popular Stories and Research Papers of 2018
Cirrus Foroughi, and Barbara Larson. Developing Novel Drugs This paper by Joshua Krieger and colleagues contributes to our understanding of how financing constraints affect the direction of innovation in View Details
Keywords: by Sean Silverthorne
- 01 Jun 2009
- Lessons from the Classroom
The Challenges of Investing in Science-Based Innovation
he made the decision to continue investing in longer-term research rather than short-term profit after Merck took its blockbuster drug Vioxx off the market in September 2004. "He believed that the only way for Merck to recover was to... View Details
- Profile
Henry McCance
a few FDA-approved drugs for Alzheimer’s disease, and they won’t help,’” he recalls. McCance, a venture- capital pioneer with Greylock Partners, had spent 40 years as eyewitness to advances in technology that changed the world at... View Details
- Student-Profile
A Jay Holmgren
of papers examining the efficacy of hospital IT systems at flagging and preventing adverse drug events. He credits the diverse expertise of his fellow doctoral students with helping him expand and enrich his research pursuits. “I’ve... View Details
- 01 Dec 2006
- News
Faculty Books
from its character as a science-based business. This poses three challenges: how to finance risky investments with long time horizons for R&D; keep pace with advances in drug knowledge; and integrate capabil-ities across the spectrum of... View Details
- 01 Mar 2011
- News
Wyss Celebrated for Career, Conservation
orthopedic and trauma surgery. He continues to serve as chairman. In recognition of his career, the HBS Health Industry Alumni Association presented Wyss with the Beatrice D. Ellerin Alumni Achievement Award at its annual conference in November (see article "Fixing... View Details
- 01 Jun 2003
- News
Against All Odds
never accomplished by any other European country, despite 150 years of trying). If it sounds almost as difficult as bringing a profitable drug to market, maybe that’s why Ernesto Bertarelli (MBA ’93), CEO of the Swiss biotech company... View Details
- 30 Sep 2022
- News
Scaling Hope
collection of essays that D’Antonio hopes will help other parents, he writes of what he wishes he’d known in the beginning: “I wish I had known that there was hope, a lot of hope, and that recovery was likely to happen for my son. I wish I had known that my son could... View Details
- 01 Jan 2003
- News
Daniel L. Vasella, M.D.
quickly," he observes. Under his guidance, Novartis has been a leader not only in developing new drugs but in making them accessible to those in need around the globe. Dan Vasella has experienced first-hand the anguish of seriously ill... View Details